Literature DB >> 9068314

Hypercalcaemia in osteogenesis imperfecta treated with pamidronate.

C J Williams1, R A Smith, R J Ball, H Wilkinson.   

Abstract

The response to the bisphosphonate, pamidronate, is reported in a child with osteogenesis imperfecta who had recurrent symptomatic hypercalcaemia after immobilisation following fractures. Oral clodronate was effective in the prevention of immobilisation hypercalcaemia in the same child. The bisphosphonates may have other roles in osteogenesis imperfecta by decreasing bone turnover.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9068314      PMCID： PMC1717065          DOI： 10.1136/adc.76.2.169

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  5 in total

1.  Is APD a promising drug in the treatment of severe osteogenesis imperfecta?

Authors:  J P Huaux; W Lokietek
Journal:  J Pediatr Orthop       Date:  1988 Jan-Feb       Impact factor: 2.324

2.  Hypercalciuria in children severely affected with osteogenesis imperfecta.

Authors:  A Chines; D J Petersen; F W Schranck; M P Whyte
Journal:  J Pediatr       Date:  1991-07       Impact factor: 4.406

3.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

4.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

Authors:  P M Boonekamp; L J van der Wee-Pals; M M van Wijk-van Lennep; C W Thesing; O L Bijvoet
Journal:  Bone Miner       Date:  1986-02

5.  Osteogenesis imperfecta in childhood: cardiac and renal manifestations.

Authors:  U Vetter; B Maierhofer; M Müller; D Lang; W M Teller; R Brenner; D Frohneberg; O Wörsdörfer
Journal:  Eur J Pediatr       Date:  1989-12       Impact factor: 3.183
  5 in total
  5 in total

1.  Zoledronic acid administration failed to prevent bone loss at the knee in persons with acute spinal cord injury: an observational cohort study.

Authors:  William A Bauman; Christopher M Cirnigliaro; Michael F La Fountaine; LeighAnn Martinez; Steven C Kirshblum; Ann M Spungen
Journal:  J Bone Miner Metab       Date:  2014-08-27       Impact factor: 2.626

Review 2.  Osteogenesis imperfecta: practical treatment guidelines.

Authors:  F Antoniazzi; M Mottes; P Fraschini; P C Brunelli; L Tatò
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

3.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

Authors:  E Aström; S Söderhäll
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

Review 4.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

5.  Current and emerging treatments for the management of osteogenesis imperfecta.

Authors:  Elena Monti; Monica Mottes; Paolo Fraschini; Piercarlo Brunelli; Antonella Forlino; Giacomo Venturi; Francesco Doro; Silvia Perlini; Paolo Cavarzere; Franco Antoniazzi
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.